Norvir, Ritonavir Newswire (Page 3)

Norvir, Ritonavir Newswire (Page 3)

Comprehensive Real-Time News Feed for Norvir, Ritonavir (generic). (Page 3)

Results 41 - 60 of 249 in Norvir, Ritonavir (generic)

  1. Antiretrovirals: A Success Storya "Celebrating 20 years of effective treatmentRead the original story w/Photo

    Jun 24, 2016 | POZ

    In early 1996, Jeffrey Pope began getting his affairs in order, straightening out his finances and his home and visiting his parents for what he assumed would be the last time. Since his AIDS diagnosis the previous year, he'd seen his CD4 count plunge from a healthy 600 to a precarious 170.

    Comment?

  2. HIV-positive children get 'sweet' ARVsRead the original story w/Photo

    Jun 17, 2016 | Daily Monitor

    KAMPALA. After receiving numerous cases of children living with HIV/Aids declining to take bitter antiretroviral drugs , leading to drug resistance, government has started giving them sugar-coated drugs.

    Comment?

  3. Sub-type C infection does not increase the risk of virologic failure...Read the original story w/Photo

    Jun 13, 2016 | Aidsmap

    Our award-winning series of booklets, with each title providing a comprehensive overview of one aspect of living with HIV. A range of interactive tools to support people living with HIV to get involved in decisions about their treatment and care.

    Comment?

  4. Week In Review: Sorrento Therapeutics Raises $150 Million From China InvestorsRead the original story w/Photo

    Jun 12, 2016 | Seeking Alpha

    Sorrento Therapeutics , a San Diego-China biopharma, closed a $150 million private placement led by Ally Bridge Group, which is headquartered in Hong Kong. The investors bought 25 million shares at $5.55 each, which was about Sorrento's price when the investment was announced on April 4. They will also receive warrants to buy 5 million additional shares at $8.50 each.

    Comment?

  5. Sub-type C infection does not increase the risk of virologic failure...Read the original story w/Photo

    Jun 8, 2016 | Aidsmap

    Our award-winning series of booklets, with each title providing a comprehensive overview of one aspect of living with HIV. A range of interactive tools to support people living with HIV to get involved in decisions about their treatment and care.

    Comment?

  6. High Doses of Imodium Linked to Cardiac Problems and DeathRead the original story

    Jun 7, 2016 | Journal Watch

    The FDA is cautioning that higher-than-recommended doses of the antidiarrheal drug loperamide are associated with potentially fatal cardiac problems. The drug is increasingly being misused for its opioid effects by patients either seeking euphoria or self-treating for opioid withdrawal.

    Comment?

  7. Court Report - June 2016Read the original story w/Photo

    Jun 6, 2016 | JD Supra

    Orexo AB et al. v. Actavis Elizabeth LLC et al. 1:16-cv-00397; filed May 27, 2016 in the District Court of Delaware Infringement of U.S. Patent No.

    Comment?

  8. Frontier Biotech 's Long-Acting HIV-1 Fusion Inhibitor Albuvirtide...Read the original story

    Jun 5, 2016 | BioSpace

    Frontier Biotech 's Long-Acting HIV-1 Fusion Inhibitor Albuvirtide Meets 48-Week Primary Objective: Interim Results Of A Phase 3 Trial /PRNewswire/ -- Frontier Biotechnologies Inc. today reported that a phase 3 clinical trial of its lead product albuvirtide meets primary objective based on an interim analysis. The results demonstrated that once-weekly given albuvirtide plus ritonavir-boosted lopinavir was non-inferior to WHO-recommended second-line three-drug regimen at 48-week in treatment experienced HIV-1 infected adults.

    Comment?

  9. Frontier Biotech's Long-acting HIV-1 Fusion Inhibitor Albuvirtide...Read the original story w/Photo

    Jun 5, 2016 | PR Newswire

    Frontier Biotech's Long-acting HIV-1 Fusion Inhibitor Albuvirtide Meets 48-Week Primary Objective: Interim Results of a Phase 3 Trial /PRNewswire/ -- Frontier Biotechnologies Inc. today reported that a phase 3 clinical trial of its lead product albuvirtide meets primary objective based on an interim analysis. The results demonstrated that once-weekly given albuvirtide plus ritonavir-boosted lopinavir was non-inferior to WHO-recommended second-line three-drug regimen at 48-week in treatment experienced HIV-1 infected adults.

    Comment?

  10. Technavio Announces Top Three Trends for the Infectious Disease...Read the original story

    Jun 1, 2016 | Information Technology

    Technavio's latest infectious disease treatment market in China report highlights three key emerging trends predicted to impel market growth through 2020. Technavio defines an emerging trend as something that has potential for significant impact on the market and contributes to its growth or decline.

    Comment?

  11. Conflicting Reports on Whether Having HIV Affects Hepatitis C Cure RatesRead the original story w/Photo

    May 23, 2016 | POZ

    Two recent studies have come to conflicting conclusions about whether HIV coinfection affects the chance of achieving a hepatitis C virus cure through direct-acting antiviral treatment in a real-world setting, aidsmap reports. Researchers presented these studies at the 51st International Liver Congress in Barcelona.

    Comment?

  12. Your 2016 Guide to Investing in Gilead Sciences StockRead the original story w/Photo

    May 23, 2016 | Fox News

    Gilead Sciences is one of the largest biotechnology companies, so you might be interested in how it makes money. If you're considering an investment in Gilead Sciences, you might also want to know how the company plans to make money in the future, and whether or not it's on firm financial ground.

    Comment?

  13. Monthly News Update: July 2015Read the original story w/Photo

    Jul 30, 2015 | Drugs.com

    Sanofi and Regeneron's Praluent , the first in a potential blockbuster class of cholesterol-reducing agents known as PCSK9 inhibitors, was FDA-approved on July 24, 2015. Praluent use is approved in adult patients with heterozygous familial hypercholesterolemia or patients with clinical atherosclerotic cardiovascular disease such as a heart attack or stroke, who require further LDL lowering.

    Comment?

  14. The big news from the recent European liver conferenceRead the original story w/Photo

    May 16, 2016 | POZ

    The 51st International Liver Congress, the annual meeting of the European Association of the Study of the Liver , took place from April 13 to 17 in Barcelona. As in recent years, hepatitis C virus news dominated.

    Comment?

  15. Does having HIV affect response to hepatitis C treatment?Read the original story w/Photo

    May 16, 2016 | Aidsmap

    Our award-winning series of booklets, with each title providing a comprehensive overview of one aspect of living with HIV. A range of interactive tools to support people living with HIV to get involved in decisions about their treatment and care.

    Comment?

  16. Conformational Energy Landscape of the Ritonavir MoleculeRead the original story

    May 13, 2016 | CiteULike

    To insert individual citation into a bibliography in a word-processor, select your preferred citation style below and drag-and-drop it into the document. Conformational polymorphism of ritonavir, a well-known pharmaceutical drug, is intricately linked to its efficacy in the treatment of acquired immunodeficiency syndrome .

    Comment?

  17. WHO issues new hepatitis C guidelines, EASL guidelines update forthcoming in SeptemberRead the original story w/Photo

    May 12, 2016 | Aidsmap

    Our award-winning series of booklets, with each title providing a comprehensive overview of one aspect of living with HIV. A range of interactive tools to support people living with HIV to get involved in decisions about their treatment and care.

    Comment?

  18. U.S. Government Updates Guidelines for HIV Post-Exposure ProphylaxisRead the original story w/Photo

    May 10, 2016 | HIV and Hepatitis

    The U.S. Centers for Disease Control and Prevention and Department of Health and Human Services in April issued their latest guidelines for non-occupational post-exposure prophylaxis for people potentially exposed to HIV through sex or shared injection equipment. The update includes new antiretrovirals approved since the last revision, with the preferred regimen now being raltegravir or dolutegravir plus tenofovir/emtricitabine .

    Comment?

  19. EASL 2016: WHO Issues New Hepatitis C Guidelines, EASL Guidelines Update ComingRead the original story w/Photo

    May 8, 2016 | HIV and Hepatitis

    In April, coinciding with the International Liver Congress in Barcelona, the World Health Organization released an update to its Guidelines for the Screening, Care and Treatment of Patients with Chronic Hepatitis C Infection . The guidelines promote the transition to newer, more effective direct-acting antiviral medications that have the potential to cure most people living with hepatitis C. Also during the meeting the European Association for the Study of the Liver announced it would update its hepatitis C treatment guidelines at a special conference in September.

    Comment?

  20. EASL 2016: Does Having HIV Affect Response to Hepatitis C Treatment?Read the original story w/Photo

    May 4, 2016 | HIV and Hepatitis

    A study from the U.S. Veterans Health Administration found that HIV-positive people responded as well as those without HIV to direct-acting antiviral therapy for hepatitis C, while a Spanish study showed that HIV/HCV coinfected people were less likely to be cured. These conflicting findings, presented at the European Association for the Study of the Liver's International Liver Congress last month in Barcelona, indicate that the interactions between HIV and hepatitis C are still not fully understood.

    Comment?